Compare Marqeta Inc (MQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Natera Inc. Common Stock — how do they compare? Marqeta Inc trades at $18.39 (market cap $1.89B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 30.2× Marqeta Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Natera Inc. Common Stock for 0 Days on average.
| MQ | NTRA | |
|---|---|---|
Market Cap | $1.89B | $57.03B |
Volume | 809,068 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $20.32 | $425.64 |
52-Week Low | $15.04 | $179.42 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.21B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.56, up 1.48% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported three consecutive quarterly EPS beats, with Q3 2026 results expected soon. Revenue has recovered from $507M in 2024 to $625M in 2025, though net income remains negative. Positive cash flow trends emerged in 2025, with net cash flow turning positive at $86M.
The outlook is mixed: strong operational momentum and partnerships (e.g., with Google and BVNK) support growth, but high valuation ratios (P/E 206.22) and thin net margins (1.53%) pose risks. Analyst consensus is cautious with a $11.38 price target, implying downside, yet institutional sentiment is divided amid earnings improvements.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
